Vimian Group AB
STO:VIMIAN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
23.7617
46.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VIMIAN stock under the Base Case scenario is 45.3 SEK. Compared to the current market price of 42.1 SEK, Vimian Group AB is Undervalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vimian Group AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VIMIAN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vimian Group AB
Balance Sheet Decomposition
Vimian Group AB
Current Assets | 190.4m |
Cash & Short-Term Investments | 41.2m |
Receivables | 73.2m |
Other Current Assets | 75.9m |
Non-Current Assets | 806.2m |
Long-Term Investments | 49.1m |
PP&E | 36.5m |
Intangibles | 718.5m |
Other Non-Current Assets | 2.1m |
Current Liabilities | 94.8m |
Accounts Payable | 25.7m |
Accrued Liabilities | 15.8m |
Other Current Liabilities | 53.3m |
Non-Current Liabilities | 225.5m |
Long-Term Debt | 178.6m |
Other Non-Current Liabilities | 46.9m |
Earnings Waterfall
Vimian Group AB
Revenue
|
344.6m
EUR
|
Cost of Revenue
|
-182m
EUR
|
Gross Profit
|
162.6m
EUR
|
Operating Expenses
|
-123.4m
EUR
|
Operating Income
|
39.2m
EUR
|
Other Expenses
|
-29.4m
EUR
|
Net Income
|
9.8m
EUR
|
Free Cash Flow Analysis
Vimian Group AB
EUR | |
Free Cash Flow | EUR |
VIMIAN Profitability Score
Profitability Due Diligence
Vimian Group AB's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Vimian Group AB's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
VIMIAN Solvency Score
Solvency Due Diligence
Vimian Group AB's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Vimian Group AB's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VIMIAN Price Targets Summary
Vimian Group AB
According to Wall Street analysts, the average 1-year price target for VIMIAN is 47.94 SEK with a low forecast of 28.28 SEK and a high forecast of 68.25 SEK.
Dividends
Current shareholder yield for VIMIAN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vimian Group AB operates as an animal health company. The company is headquartered in Stockholm, Stockholm and currently employs 1,068 full-time employees. The company went IPO on 2021-06-18. The firm is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The firm invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.
Officers
The intrinsic value of one VIMIAN stock under the Base Case scenario is 45.3 SEK.
Compared to the current market price of 42.1 SEK, Vimian Group AB is Undervalued by 7%.